BioWorld

June 24, 2004

Safety Issues Force IntraBiotics To Halt Iseganan VAP Program

Just as researchers geared up to start a second pivotal trial of iseganan in ventilator-associated pneumonia (VAP), the floor fell from beneath IntraBiotics Pharmaceuticals Inc. Wednesday. (BioWorld Today) Read More

Exelixis Begins Phase III Trial Of XL119 In Bile Duct Cancer

PTC Raises Another $15M To Close Series E At $50M

Millennium Shifts Integrilin In Europe From Schering To GSK

Kosan, Roche Stop Colorectal Cancer Trial, Shift To Prostate

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 18, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 18, 2025.

Apollo’s APL-4098 shows potent antileukemic effects

BioWorld Science

Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...